Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the receptor‐mediated signaling of multiple cytokines...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmacol Res Perspect
Egile Nagusiak: Dowty, Martin E., Lin, Tsung H., Jesson, Michael I., Hegen, Martin, Martin, David A., Katkade, Vaibhav, Menon, Sujatha, Telliez, Jean‐Baptiste
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857076/
https://ncbi.nlm.nih.gov/pubmed/31832202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.537
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak